Drug Profile
Ralinepag - Pfizer/United Therapeutics Corporation
Alternative Names: APD-811Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Arena Pharmaceuticals
- Developer Pfizer; United Therapeutics Corporation
- Class Acetic acids; Antihypertensives; Carbamates; Chlorobenzenes; Small molecules
- Mechanism of Action Epoprostenol receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Pulmonary arterial hypertension
Most Recent Events
- 02 Aug 2023 United Therapeutics Corporation plans to launch ralinepag in pulmonary arterial hypertension
- 29 Nov 2022 Phase-III development is ongoing Argentina, Australia, Belgium, Bulgaria, Canada, China, Croatia, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, Spain, Sweden, Ukraine, Taiwan, Brazil, Czech Republic, Israel, South Korea, Poland, Singapore, United Kingdom, Austria, USA
- 29 Nov 2022 Phase-III development is ongoing in Brazil, Czech Republic, Israel, South Korea, Poland, UK, Austria, Singapore (NCT03626688)